Effect of compound bone peptide injection on osteoporotic fractures of thoracolumbar spine, bone density and bone metabolism / 药学实践杂志
Journal of Pharmaceutical Practice
; (6): 557-560, 2021.
Article
在 Zh
| WPRIM
| ID: wpr-904760
Responsible library:
WPRO
ABSTRACT
Objective To evaluate the clinical value of compound bone peptide injection in patients with thoracolumbar osteoporotic fracture. Methods 96 patients admitted from January 2018 to January 2020 with thoracolumbar osteoporotic fracture were selected. The patients were randomly divided into group A (receiving calcine D with compound bone peptide injection) and group B (receiving calcine D treatment) with 48 patients in each group. TCM symptom scores, bone metabolism, degree of osteoporosis, bone density level, visual analogue scale (VAS) and lumbar spine disease treatment score (JOA) were compared between the two groups after treatment. Results After treatment, the TCM symptom score and JOA score in group A were higher than those in group B (P<0.05). The levels of bone alkaline phosphatase (BALP) and type I procollagen N-terminal propeptide (PIINP) in group A were significantly lower than those in group B (P<0.05). The grade 3 osteoporosis ratio in group A was lower than that in group B (P<0.05). The bone mineral density level in group A was higher than that in group B (P<0.05). The visual analogue scale (VAS) in group A was lower than that in group B (P<0.05). Conclusion The treatment of thoracolumbar osteoporotic fracture with compound bone peptide injection effectively improved the bone metabolism and bone mineral density, relieved pain and promoted the recovery of lumbar function.